BioMarin Official Calls Drisapersen AdCom ‘Critical Thinking On Display’
Executive Summary
CMO says advisory committee was tough on proposed Duchenne muscular dystrophy treatment in part because it was first to reach that stage.
You may also be interested in...
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.
Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.